Navigation Links
Drug-eluting stents safe, effective for treatment of chronic total occlusions
Date:9/21/2009

SAN FRANCISCO, CA SEPTEMBER 21, 2009 A multicenter study in Asia found drug-eluting stents effective with a low rate of acute complications in patients with chronic total occlusions (CTOs) undergoing PCI. Results of the study will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

The aim of the study, "Drug-Eluting Stents for the Treatment of Chronic Total Occlusion: A Comparison with Sirolimus (SES), Paclitaxel (PES), Zotarolimus (ZES), Biolimus A9 (BES), EPC Capture (ECS) and Everolimus-Eluting Stent (EES): Multicenter Registry in Asia" is to compare the safety and efficacy of SES, PES, ZES, BES, SCS and EES in the treatment of patients with chronic total occlusion (blockage) of cardiac blood vessels. The study will be presented as a poster abstract (TCT-234) on Tuesday, September 22 between 8:00 a.m. and 10:00 a.m. in Hall D of The Moscone Center.

For the study, researchers led by Sunao Nakamura, MD, performed a prospective analysis of 1,148 patients with 1,253 CTOs treated with different drug-eluting stents (396 SES, 526 PES, 177 ZES, 66 BES, 41 ECS, and 43 EES) in six high volume Asian centers after successful CTO re-canalization was performed.

Dr. Nakamura, who will report on the results of the investigations, is Vice President and Director of the Cardiovascular Center at New Tokyo Hospital as well as Clinical and Visiting Professor of Kumamoto University in Matsudo, Japan.

The researchers found that the incidence of major adverse cardiac events (MACE) at 30 days was nearly non-existent in patients with CTO lesions treated with drug-eluting stents (0.4% in patients with PES, 0.6% in ZES and 0% in all other categories). MACE at 9 months was 3.6% for those receiving SES, 6.7% for PES, 10.4% for ZES, 4.5% for BES, 10.3% for ECS and 2.4% for EES. Target lesion revascularization (TLR) at 9 months was 3.6% for patients who received SES, 6.7% for PES, 10.4% for ZES, 4.5% for BES, 10.3% for ECS and 2.4% for EES.

In addition, patients treated with SES, BES and EES showed a lesser rate of angiographic restenosis compared with other drug-eluting stents at 9 months (4.0% restenosis for patients receiving SES, 6.7% for PES, 12.3% for ZES, 4.5% for BES, 10.3% for ECS and 2.4% for EES).

In conclusion, Dr. Nakamura noted that, "The study indicates a good clinical performance of the new BES and EES devices."


'/>"/>

Contact: Judy Romero
jromero@crf.org
347-407-2774
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Researchers find drug-eluting stents safe, effective for PCI in diabetics
2. Analysis of drug-eluting stents data demonstrates safety, efficacy in on-and-off-label use
3. NEJM study finds drug-eluting stents more effective than bare-metal stents in heart attack patients
4. CorNova to Present at the Glimpse into the Future: Emerging Drug-Eluting Stents Symposium at EuroPCR 2009
5. No Increase in Clots With Drug-Eluting Stents
6. Drug-eluting stents found safe, superior to bare metal stents
7. XTENT Receives CE Mark Approval for CUSTOM NX (R) Drug-Eluting Stent System
8. Drug-Eluting Stents Show Promise for Leg Arteries
9. Promising Three-year Data: Saving Limbs With Drug-Eluting Stents
10. Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System
11. SYNTAX defines borders between CABG and PCI with TAXUS drug-eluting stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... On May ... Aqua® Research Water Life Science® and international water advocate, was honored by Ashram, Inc. ... women in ancient Egypt who knelt on the banks of the Nile to fill ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... leader Mike Morrow-Fox . With over 20 years of experience in leading technology ... well as several years of university teaching, Morrow-Fox will be featured on ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... the launch of its brand equity product, Brandvantage. This breakthrough tool leaves ... landscape of modern consumer decision-making. The proprietary framework incorporates attitudes, behavior and ...
(Date:5/26/2016)... ... May 26, 2016 , ... In Madeira Beach Florida, a small ... single drawbridge, citizens formed an organization, Madeira Beach United, to oppose two development projects ... small town center to a high rise urban environment. , According to the ...
(Date:5/26/2016)... ... May 26, 2016 , ... Women’s ... to host their second pop-up shop for three consecutive weekends. The pop-up shop ... the Santa Barbara community, a community full of women who appreciate the most ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... , May 26, 2016 ... has matured into an essential life science tool for ... development applications. BCC Research reveals in its new report ... second growth phase, one powered by a range of ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
(Date:5/25/2016)... Germany and GERMANTOWN, Maryland ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... and co-development agreement with Therawis Diagnostics GmbH to develop and ... to develop and market PITX2 as a marker to predict ... breast cancer patients. "We are pleased to partner ...
(Date:5/25/2016)... As illustrated by the Spring ... the numbers and momentum of cannabis in the US ... billions, more research and development push the sector forward. ... Legal Marijuana Markets Report  from from ArcView Market Research ... the increase in sector is attributed to adult use ...
Breaking Medicine Technology: